On December 13, 2021, Arena Pharmaceuticals, Inc. (the Company or Arena), entered into an Agreement and Plan of Merger, dated December 12, 2021 (the Merger Agreement), with Pfizer Inc. (Parent), and Antioch Merger Sub, Inc.
On March 11, 2022, the Company completed its merger with Merger Sub pursuant to the terms of the Merger Agreement, whereby Merger Sub merged with and into the Company, in accordance with the General Corporation Law of the State of Delaware (the DGCL), with the Company continuing as the surviving corporation (the Surviving Corporation) and as a wholly owned subsidiary of Parent (the Merger). Pursuant to the Merger Agreement, effective as of, and contingent upon, the occurrence of the closing of the Merger (the Closing), each of Amit D. Munshi, Tina S. Nova, Garry Neil, Jayson Dallas, Jennifer Jarrett, Oliver Fetzer, Kieran T. Gallahue, Katharine Knobil, Nawal Ouzren and Steven J. Schoch ceased serving as a member of the board of directors of the Company and each committee thereof.